EVO Similar Chart Price Prediction
The price of EVO is predicted to go up -8.22%, based on the high correlation periods with SQM. The similarity of these two price pattern on the periods is 92.01%.
EVO
SQM
Down: -8.22%Similarity: 92.01%
EVO Revenue Forecast
EVO EPS Forecast
EVO FAQs
What is EVO revenue forecast for next quarter？
EVO VS S&P500
Evotec's focus on building out its biologics manufacturing capacity makes it well positioned to capture heightened demand for biologics by biopharma companies.
Drug manufacturing outsourcing levels continue to steadily increase, and Evotec should benefit as biopharma clients seek CDMO services.
The commercial success of Evotec's proprietary assets would bring high-margin, recurring royalty revenue to the firm.
EVO Analyst's Forecast
Benjamin Jackson
Jefferies
Strong Buy → Hold
2024-10-07
Price Target
$8.7 → $3.8
Upside
+13.77%
Jefferies downgraded Evotec to Hold from Buy with a price target of $3.80, down from $8.70. The firm expects Evotec's strategic reset to take time, with "lingering uncertainty over when the market will recover." A lack of clarity over the business trajectory in 2025 and beyond, plus risk of further delays to the strategy update, "could amplify concerns further," the analyst tells investors in a research note.
